Fritextsökning
Innehållstyper
-
Collaboration in laboratory automation
The Dutch company Synchron Lab Automation developed an automated DNA extraction system with high throughput, working very closely together with Festo. As a resu...
-
Editorial: ”AI that both impresses and frightens”
”In the past, I've rarely been particularly impressed by something that was produced by AI. But this is something completely different”, Samuel Lagercrantz writ...
-
Learn from Speakers from Leading MedTech Companies
Watch the recordings from ZEISS Quality Innovation Days whenever it suits you.
-
Samuel Lagercrantz: “Companies that do this successfully will take the lead”
The development of new medicines and medical technologies should not focus too narrowly on prolonging life. It is equally important to develop treatments that r...
-
The new ZEISS Celldiscoverer 7 has been launched
Adaptable automation for advanced workflows.
-
Jättestudie om mjölk: Riskfyllt för kvinnor men inte för män
Risken för hjärtinfarkt ökade för kvinnor som i genomsnitt drack minst två glas mjölk om dagen, medan det hos män inte återfanns något sådant samband i en ny st...
-
Branschkritik mot EU:s nya läkemedelsförslag – ”En försämring”
”Som helhet en försämring”. ”En förlorad möjlighet”. Så reagerar svenska och europeiska branschorganisationer på kompromissen om en ny läkemedelslagstiftning i EU.
-
Öppen frågestund: Regulatory Opportunities for Rare Diseases/Orphan Products in US and EU
Anmäl dig till vår nästa session av Office Hours den 28 februari klockan 15:00 (svensk tid), en öppen frågestund om utveckling av särläkemedel (orphan drugs).
-
Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”
It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic hav...
-
Från apotekare till poddare – Magnus Lejelöv har rösten som verktyg
Magnus Lejelöv har över 20 års erfarenhet från läkemedelssektorn och har intervjuat nära två hundra vårdprofiler i sina poddar. I maj står han på scenen i Lund ...
-
Join us at SLAS Barcelona
Festo LifeTech is exhibiting at the SLAS in Barcelona.
-
Conjugate Planes in Microscopy
Knowledge Article from ZEISS.
-
EMA review confirms a risk of new cancer after CAR-T
CAR-T cancer therapies can, in rare cases, induce secondary cancers. The European Medicines Agency (EMA) now recognises this and requires a warning label to be ...
-
List: The coolest names in biotech
Hairy beasts, volcanic material and space strolling stand out on a US list of the best biotech company names, and on a list of the coolest names for pharmaceuti...
-
Eternal Rye – Improving Plant Breeding Methods
User story from Martin Luther University Halle.
-
Vinnova is going to establish a new innovation cluster
Vinnova, the Swedish Agency for Innovation Systems, has been commissioned by the government to establish a national innovation cluster for advanced medicines.
-
Automated opening and closing of sample vials
From technical requirements to a suitable solution
-
Accurate removal of prostate tissue
Medical robots play an important role in diagnostics
-
Assignment: Facilitate the retention of foreign researchers
A newly appointed public inquiry is to develop measures to make attracting and retaining foreign doctoral students and researchers in Sweden easier.
-
Basics of Confocal Laser Scanning Microscopy
Learn about the principle of confocal fluorescence microscopy.
-
How Volume EM Advances Life Science Research
Free webinar series.
-
Recipharm divests five Swedish plants
Swedish contract manufacturer Recipharm is selling its facilities in Solna, Strängnäs, Höganäs, Karlskoga and Uppsala OTC Development to US private equity compa...
-
FDA-beslut: AZ:s nasala influensavaccin får tas av patienten själv
Astra Zenecas nasala influensavaccin Flumist har godkänts för självadministrering i USA. Det är därmed det första influensavaccinet i USA som inte behöver ges av en vårdgivare.
-
Settlement of cancer allegations against blockbuster drug
French pharmaceutical company Sanofi has reached a principal agreement in the US on around 4,000 of the cases in which its now withdrawn blockbuster heartburn d...
BREAKING